NADH-IN-1 |
| Catalog No.GC70952 |
NADH-IN-1 a une activité inhibitrice de NADH:ubiquinone oxidoréductase avec une valeur ci50 de 27 μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1432445-15-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NADH-IN-1 (1 μM) exhibits a short half-life and fast intrinsic clearance indicating that it is readily metabolised by the liver in vivo; shows no adverse effects on primary rat hepatocytes, and does not inhibit the hERG channel[1].
NADH-IN-1 (10 mg/kg; IV or PO; single dosage) produces no observable toxic effects at 10 mg/kg by IV or PO; exhibits a short half-life and high plasma clearance; exhibits high mouse and human serum protein binding, as well as moderate bioavailability[1].
References:
[1]. Devine R, et al. Design, synthesis, and biological evaluation of aryl piperazines with potential as antidiabetic agents via the stimulation of glucose uptake and inhibition of NADH:ubiquinone oxidoreductase. Eur J Med Chem. 2020;202:112416.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *